Login

Merus N.V. 8-K SEC Filings

Filed On Filing
30 Dec 2025 8-K: Completion of Acquisition or Disposition of Assets; Notice of Delisting or Failure to Satisfy a Listing Rule +2 more

As previously disclosed by Merus N.V., a public limited liability company (naamloze vennootschap) organized under the laws of The Netherlands (the “Company”), on September 29, 2025, the Company entered into a Transaction Agreement (as it...

12 Dec 2025 8-K: Completion of Acquisition or Disposition of Assets; Material Modification to Rights of Security Holders +2 more

In connection with the Transaction Agreement, dated September 29, 2025 (the “Transaction Agreement”) by and between Genmab A/S, a public limited liability company (Aktieselskab) organized under the laws of Denmark (“Parent”), Genmab Hold...

09 Dec 2025 8-K: Submission of Matters to a Vote of Security Holders

On December 9, 2025, Merus N.V., a public limited liability company (naamloze vennootschap) organized under the laws of the Netherlands (“Merus” or the “Company”), held an extraordinary general meeting of its shareholders (the “EGM”) to ...

29 Sep 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Exhibit A – Principles of Amended Articles of Association after Conversion

05 Jun 2025 8-K: Entry into a Material Definitive Agreement

Merus N.V., a public limited liability company incorporated under the laws of the Netherlands (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representativ...

29 May 2025 8-K: Other Events

Merus, N.V. (the “Company”) is providing the following updates.

22 May 2025 8-K: Submission of Matters to a Vote of Security Holders

On May 21, 2025, Merus N.V. (the “Company”) held its annual general meeting of shareholders (the “Annual Meeting”). For all proposals, a total of 61,712,250 common shares were present or represented by proxy at the Annual Meeting, repres...

05 Dec 2024 8-K: Other Events

On December 4, 2024, Merus N.V. announced that the United States Food and Drug Administration has approved BIZENGRI® (zenocutuzumab-zbco) for treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NS...

02 Dec 2024 8-K: Entry into a Material Definitive Agreement

On November 27, 2024 (the “Effective Date”), Merus N.V., a public company with limited liability incorporated under the laws of the Netherlands (the “Company”) entered into a License Agreement (the “License Agreement”) with Partner Thera...

05 Nov 2024 8-K: Other Events

On November 5, 2024, Merus N.V. announced that the United States Food and Drug Administration has extended the Prescription Drug User Fee Act goal date for the biologics license application for zenocutuzumab (Zeno) to February 4, 2025.

01 Jul 2024 8-K: Departure/Election of Directors or Officers; Compensation

This Employment Agreement (this “Agreement”), dated as of June 30, 2024, is made by and between Merus US, Inc., a Delaware corporation (together with any successors or assigns, the “Company”), and F. Zohren (“Executive”) (collectively re...

30 May 2024 8-K: Entry into a Material Definitive Agreement

Merus N.V., a public limited liability company incorporated under the laws of the Netherlands (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representativ...

28 May 2024 8-K: Other Events

Merus, N.V. (the “Company”) is providing the following updates.

08 May 2024 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

06 Mar 2024 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

On March 5, 2024, we entered into a collaboration, option and license agreement (“Collaboration Agreement”) and Share Subscription Agreement (the “Subscription Agreement”) with Gilead Sciences, Inc. (“Gilead”). Under the terms of the Col...

11 Aug 2023 8-K: Entry into a Material Definitive Agreement

Merus N.V., a public limited liability company incorporated under the laws of the Netherlands (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representativ...

15 Jun 2023 8-K: Departure/Election of Directors or Officers; Compensation

This Employment Agreement (this “Agreement”), dated as of June 14, 2023, is made by and between Merus US, Inc., a Delaware corporation (together with any successors or assigns, the “Company”), and Gregory Perry (the “Executive”) (collect...

30 May 2023 8-K: Submission of Matters to a Vote of Security Holders

On May 26, 2023, Merus N.V. (the “Company”) held its annual general meeting of shareholders (the “Annual Meeting”). For all proposals, a total of 36,347,050 common shares were present or represented by proxy at the Annual Meeting, repres...

23 May 2023 8-K: Termination of a Material Definitive Agreement

As previously disclosed, on May 7, 2021, Merus N.V. (the “Company”) entered into an Open Market Sale AgreementSM (the “Sales Agreement”), with Jefferies LLC (“Jefferies”), to sell, at its option, its common shares, nominal value €0.09 pe...

17 Apr 2023 8-K: Other Events

Merus, N.V. (the “Company”) is providing the following updates.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support